Back to top

Context downgraded to Market Perform from Outperform at LifeSci Capital

LifeSci Capital analyst Charles Zhu downgraded Context Therapeutics (CNTX) to Market Perform from Outperform. Published first on TheFly – the ultim...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Context Therapeutics Inc. (CNTX)